Hard To Treat Diseases (HTDS) exclusive agent and partner of NCPC
NCPC is the biggest modern Pharmaceutical manufacturer in
In accordance with the agreement, Mellow Hope was appointed as the exclusive agent and partner of NCPC for its international marketing of Recombinant Hepatitis B Vaccine (CHO).
With the world’s largest population and 17 million newborn babies each year,
Large population, many newborns
Poliomyelitis vaccine 68 million doses Diphtheria-pertussistetanus vaccine 68 million doses Hepatitis B vaccine 51 million doses Measles vaccine 34 million doses BCG vaccine 17 million doses
The aforementioned statistics and data were obtained from the following sources without permission
http://bioplanassociates.com (Direct link bellow) http://bioplanassociates.com/publications/articles/VACCINES_China_Zhou_Apr07_C hinaB.pdf
The HTDS management sees this agent agreement as a great potential boost of its revenue streams in introducing International marketing of Recombinant Hepatitis B Vaccine(CHO) to Mellow Hope’s already existing distribution network.
In other company news, the company IP progress, Q2 financials and other corporate business matters are in the process of undergoing final review. These will be filed shortly and followed with an announcement.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision’s under the Private Securities Litigation Reform Act of 1995. The words or phrases “can be,” “expects,” “may affect,” “believed,” “estimate,” “project,” and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.’s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.’s control. In addition to those discussed in Hard to Treat Diseases, Inc.’s press releases, public filings, and statements by Hard to Treat Diseases, Inc.’s management, including, but not limited to, Hard to Treat Diseases, Inc.’s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.’s ability to raise additional capital to fund future operations, HTDS Corporation’s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.’s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
SOURCE Hard to Treat Diseases